Invitrogen Corporation (Nasdaq:IVGN), a leading life sciences company with a broad portfolio of technologies to improve and accelerate biomedical research, drug discovery and commercial bioproduction, unveiled its latest concept in bioinformatics and systems biology with the launch of i-Path at the BIO 2005 international conference.
A new resource for scientists worldwide, i-Path consists of 225 high-level, annotated, validated original maps of human cell signaling and metabolic pathways compiled by GeneGo Inc, a leading provider of databases and software for systems biology. Invitrogen scientists have further identified the specific antibodies, siRNA, full-length DNA clones and other biological molecules involved in cell function and disease on these maps. The system enables researchers to visualize molecular interactions in a highly graphical, user-friendly, interactive format and will be available to scientists free of charge on Invitrogen's Web site."i-Path continues our tradition of providing enabling, Web-based technologies to support researchers throughout their experiments," said Michael Stapleton, Vice President & General Manager eCommerce and Bioinformatics for Invitrogen. "Building on a rich history that includes the acquisition of InforMax, Invitrogen has moved powerful design and analytic capabilities into the mainstream of science by coupling these systems with familiar research tools and making them freely available through our Web site."